ReviewJournal of clinical medicine2023
Gonadotropin-Releasing Hormone Antagonists-A New Hope in Endometriosis Treatment?
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.Archives of gynecology and obstetrics · 2025Pooled it
- Serum biomarkers associated with disease stage and pain severity among women with endometriosis in Indonesia.Narra J · 2026Article
- The Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- Preserving Fertility in Young Women: Triple-Step Strategy for Managing Giant Endometriomas With Minimal AMH Decline-A Case Report.Case reports in obstetrics and gynecology · 2026Article
- Ovarian Reserve Following Triple-Step Procedure on Bilateral Large Endometrioma: A Retrospective Study from Bali, Indonesia.International journal of women's health · 2026Article
- Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.Biomedicines · 2025Review
- The Multifactorial Pathogenesis of Endometriosis: A Narrative Review Integrating Hormonal, Immune, and Microbiome Aspects.Medicina (Kaunas, Lithuania) · 2025Review
- Endometriosis in Adolescence: A Narrative Review of the Psychological and Clinical Implications.Diagnostics (Basel, Switzerland) · 2025Review
- Central Serous Chorioretinopathy in Endometriosis Treatment with Progestogen: A Metabolic Understanding.Life (Basel, Switzerland) · 2025Article
- Identification and analysis of oxidative stress-related genes in endometriosis.Frontiers in immunology · 2025Article
- Broadening horizons: microbiota as a novel biomarker and potential treatment for endometriosis.Frontiers in microbiology · 2025Review
- Dermatological care of gender-diverse patients in Australia.The Australasian journal of dermatology · 2024Review
- Endometriosis: Future Biological Perspectives for Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023.Facts, views & vision in ObGyn · 2024Article
- Premenstrual syndrome: new insights into etiology and review of treatment methods.Frontiers in psychiatry · 2024Review
- Targeting c-MYC: a potential non-hormonal therapeutic approach for endometriosis treatment.Frontiers in cell and developmental biology · 2023Article
- Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic disease, in which endometrial-like tissue is found outside the uterine cavity. Lesions are typically located in the true pelvis but can be found, in addition to extragenital endometriosis, in the respiratory system, the diaphragm, the pleura or the pericardium. As the extrauterine endometrial lesions undergo the menstrual cycle, they cause many symptoms, including pain, and besides infertility, they all mostly affect the quality of the patient's life. Pharmacological management of endometriosis significantly increases in importance either as a first-line treatment or as a complementary therapy after surgery. Yet, current research on antagonists of the gonadotropin-releasing hormone (GnRH) has revealed their potential benefits in endometriosis treatment. Their mechanism of action is to down-regulate the hypothalamic-pituitary-gonadal axis and therefore induce a hypoestrogenic state. The resulting reduction of estrogen levels prevents disease progression and diminishes the recurrence rate after surgical removal of endometriosis. The present review summarizes recent reports of the role oral GnRH antagonists have as a significant treatment option for pain reduction in endometriosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.